This article provides a detailed overview of pharmacology of Cholinergic and Adrenergic Receptors:, the pharmacokinetics and pharmacodynamics of drugs acting on them, their classification, therapeutic uses, adverse effects, and their crucial role in the management of disorders such as glaucoma, myasthenia gravis, and organophosphorous poisoning.
The autonomic nervous system (ANS) is divided into the sympathetic and parasympathetic divisions, each operating through specific receptors: adrenergic and cholinergic, respectively. These receptors mediate the actions of endogenous neurotransmitters—norepinephrine, epinephrine, and acetylcholine—and are central to pharmacological interventions in various clinical conditions.
1. Pharmacology of Cholinergic and Adrenergic Receptors: Cholinergic Receptors
Cholinergic receptors respond to acetylcholine (ACh) and are broadly divided into:
A. Muscarinic Receptors (M1–M5)
- Location: Smooth muscles, cardiac muscles, glands
- Function:
- M1: CNS and gastric secretion
- M2: Cardiac inhibition
- M3: Smooth muscle contraction and glandular secretion
B. Nicotinic Receptors (Nm, Nn)
- Nm: Found at neuromuscular junctions (skeletal muscle)
- Nn: Found in autonomic ganglia and adrenal medulla
2. Pharmacology of Cholinergic and Adrenergic Receptors: Adrenergic Receptors
Adrenergic receptors are activated by norepinephrine and epinephrine and divided into:
A. Alpha Receptors
- α1: Vasoconstriction, mydriasis, increased BP
- α2: Inhibits norepinephrine release (negative feedback)
B. Beta Receptors
- β1: Increased heart rate and contractility
- β2: Bronchodilation, vasodilation, uterine relaxation
- β3: Lipolysis in adipose tissue
3. Pharmacokinetics (PK) and Pharmacodynamics (PD)
A. Pharmacokinetics
- Absorption: Depends on lipid solubility; tertiary amines (e.g., atropine) cross the blood-brain barrier
- Distribution: Most agents are systemically distributed; quaternary amines are restricted
- Metabolism: Cholinergic drugs are rapidly hydrolyzed by cholinesterase; adrenergic agents metabolized by COMT and MAO
- Excretion: Renal or hepatic pathways
B. Pharmacodynamics
- Drugs bind to specific receptors → activate or block them → alter physiological function
- Receptor affinity, intrinsic activity, and receptor selectivity determine drug effects
4. Drugs Acting on Cholinergic Receptors
A. Cholinergic Agonists
- Direct-acting: Bethanechol, Pilocarpine (used in glaucoma)
- Indirect-acting (AChE inhibitors): Neostigmine, Physostigmine (used in myasthenia gravis)
B. Cholinergic Antagonists
- Muscarinic blockers: Atropine, Scopolamine (used in bradycardia, organophosphate poisoning)
- Nicotinic blockers: Tubocurarine (neuromuscular blocker), Hexamethonium (ganglion blocker)
5. Drugs Acting on Adrenergic Receptors
A. Adrenergic Agonists
- Non-selective: Epinephrine (used in anaphylaxis)
- Selective α1: Phenylephrine (nasal decongestant)
- Selective β2: Salbutamol (asthma)
- Selective β1: Dobutamine (heart failure)
B. Adrenergic Antagonists
- α-blockers: Prazosin (hypertension, BPH)
- β-blockers: Propranolol (non-selective), Atenolol (β1-selective)—used in HTN, arrhythmias, MI
6. Adverse Drug Reactions (ADRs) and Drug Interactions
A. Cholinergic Drugs
- ADRs: Bradycardia, hypotension, GI cramping, bronchospasm
- Interactions: Potentiated by other parasympathomimetics; antagonized by atropine
B. Adrenergic Drugs
- ADRs: Tachycardia, hypertension, tremors, anxiety
- Interactions: Interact with MAO inhibitors, tricyclic antidepressants, β-blockers
7. Clinical Applications and Conditions
A. Glaucoma
- Mechanism: Increased intraocular pressure due to impaired aqueous humor drainage
- Drugs Used:
- Pilocarpine: M3 agonist, contracts ciliary muscle, improves outflow
- Timolol: β-blocker, decreases aqueous humor production
B. Myasthenia Gravis
- Mechanism: Autoimmune destruction of nicotinic receptors at NMJ
- Drugs Used:
- Neostigmine, Pyridostigmine: Reversible AChE inhibitors, increase ACh at NMJ
- Atropine may be co-administered to counter muscarinic side effects
C. Organophosphorous Poisoning
- Mechanism: Irreversible AChE inhibition → ACh accumulation → cholinergic crisis
- Drugs Used:
- Atropine: Muscarinic receptor antagonist
- Pralidoxime (2-PAM): Reactivates AChE before aging
- Diazepam: Controls convulsions
8. Drug Classification Summary
| Drug Class | Example Drugs | Receptor Target | Clinical Use |
|---|---|---|---|
| Muscarinic agonists | Pilocarpine, Bethanechol | M1–M3 | Glaucoma, urinary retention |
| Muscarinic antagonists | Atropine, Scopolamine | M1–M5 | Bradycardia, OP poisoning |
| Adrenergic agonists | Epinephrine, Salbutamol | α/β receptors | Asthma, anaphylaxis |
| Adrenergic antagonists | Propranolol, Prazosin | α, β receptors | Hypertension, arrhythmias |
| AChE inhibitors | Neostigmine | ↑ ACh | Myasthenia gravis |
| Enzyme reactivators | Pralidoxime | Reactivate AChE | OP poisoning |
9. Special Considerations in Therapy
- Receptor selectivity is vital to avoid off-target effects.
- Rebound effects: Abrupt discontinuation of β-blockers can cause rebound tachycardia.
- Age and organ function influence drug metabolism and excretion.
- Monitoring of ADRs and drug interactions is crucial in polypharmacy.
10. Conclusion
A clear understanding of cholinergic and adrenergic receptors, and the drugs acting on them, forms the backbone of autonomic pharmacology. These drugs are essential in managing a range of conditions from asthma and hypertension to complex neurotoxic emergencies like organophosphorous poisoning and myasthenia gravis. The knowledge of their classification, mechanisms of action, pharmacological properties, and clinical indications empowers clinicians to prescribe with precision and safety.